DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00044707

CompletedPhase 2

Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

Lead sponsor

AstraZeneca

Asset

Pramlintide

Subcutaneous · Amylin analog

Listed sites

1

Recruiting sites

—

Enrollment

24

actual

Study population

Type 2 diabetes

Key I/E criterion

•HbA1c 6.5-11%

Primary endpoint

•Effect of pramlintide on the PK of an oral medication

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00044707
Org study ID137-154

Timeline

Milestones

Study first posted2002-09-05estimated
Last update posted2015-05-21estimated
Study start2002-08 (month precision)
Primary completion2002-09actual (month precision)
Study completion2002-09actual (month precision)

Assets

Investigational agents

Pramlintide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age60 Years
SexAll
Healthy volunteersNot accepted

Eligibility criteria

•Type 2 diabetes mellitus treated with diet and/or oral agents
•HbA1c 6.5-11.0

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints
Primary/protocol endpoint

To determine the effect of pramlintide on the PK of an oral medication

Time frame:7 Days

concentration, descriptive

Secondary/protocol endpoint

safety and tolerability as measured by analysis of laboratory values and adverse events

Time frame:7 Days

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.